AC
ADAP

Athanor Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Athanor Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-97,240
Closed -$524K – 792
2020
Q4 		$524K Buy
97,240
+34,492
+55% +$187K 0.01% 458
2020
Q3 		$501K Sell
62,748
-29,526
-32% -$258K 0.02% 339
2020
Q2 		$924K Buy
+92,274
New +$580K 0.05% 204

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Athanor Capital's ADAP Position: Q1 2021 in Review

Athanor Capital sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 97,240 shares — an estimated $524K sold.

Athanor Capital first reported a position in ADAP in Q2 2020 and held it in 3 quarters. The position peaked at $924K in Q2 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • Athanor Capital reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 97,240 Adaptimmune Therapeutics shares in Q1 2021, an estimated $524K.
  • Athanor Capital first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 3 quarters.
  • Athanor Capital's Adaptimmune Therapeutics position peaked at $924K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.